In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorCastillo García, Encarnación
dc.contributor.authorDea Ayuela, María Auxiliadora
dc.contributor.authorGonzález Álvarez, Marta
dc.contributor.authorVega, Celeste
dc.contributor.authorRolón, Miriam
dc.contributor.authorBolás Fernández, Francisco
dc.contributor.authorBorrás, Joaquín
dc.contributor.authorGonzález Rosende, María Eugenia
dc.contributor.otherUCH. Departamento de Farmacia
dc.contributor.otherProducción Científica UCH 2009
dc.date.accessioned2024-01-23T08:39:11Z
dc.date.available2024-01-23T08:39:11Z
dc.date.issued2009-11
dc.descriptionEste recurso no está disponible en acceso abierto por política de la editorial.
dc.description.abstractA series of compounds containing the nitrobenzene and sulfonamido moieties were synthesized and their leishmanicidal effect was assessed in vitro against Leishmania infantum promastigotes. Among the compounds evaluated, the p-nitrobenzenesulfonamides 4Aa and 4Ba, and the p-nitroaniline 5 showed significant activity with a good selectivity index. In a Balb/c mice model of L. Infantum, administration of compounds 4Aa, 4Ba or 5 (5 mg/kg/day for 10 days, injected ip route) led to a clear-cut parasite burden reduction (ca. 99%). In an attempt to elucidate their mechanism of action, the DNA interaction of 4Aa and 5 was investigated by means of viscosity studies, thermal denaturation and nuclease activity assay. Both compounds showed nuclease activity in the presence of copper salt. The results suggest that compounds 4Aa, 4Ba and 5 represent possible candidates for drug development in the therapeutic control of leishmaniasis.es_ES
dc.identifier.citationDea-Ayuela, M.A., Castillo, E., Gonzalez-Alvarez, M., Vega, C., Rolón, M., Bolás-Fernández, F., Borrás, J. & González-Rosende, M.E. (2009). In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. Bioorganic & Medicinal Chemistry, vol. 17, i. 21 (nov.), pp. 7449–7456. DOI: https://doi.org/10.1016/j.bmc.2009.09.030es_ES
dc.identifier.doihttps://doi.org/10.1016/j.bmc.2009.09.030
dc.identifier.issn0968-0896
dc.identifier.urihttp://hdl.handle.net/10637/15054
dc.language.isoenes_ES
dc.publisherElsevieres_ES
dc.relationEste artículo de investigación ha sido financiado por la Generalitat Valenciana (GVPRE2008/77) y por la Universidad CEU Cardenal Herrerra (PRCEU-UCH08–07). También ha recido financiación a través del CYCIT (CTQ2007–63690/BQU).
dc.relationUCH. Financiación Autonómica
dc.relationUCH. Financiación Universidad
dc.relation.ispartofBioorganic & Medicinal Chemistry, vol. 17, i. 21 (nov.)
dc.relation.projectIDGVPRE2008/77
dc.relation.projectIDPRCEU-UCH08–07
dc.relation.projectIDCTQ2007–63690/BQU
dc.rightsrestricted access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectEnfermedad transmisible
dc.subjectInfectious diseases
dc.subjectTratamiento médico
dc.subjectMedical treatment
dc.subjectMedicamento
dc.subjectDrugs
dc.subjectFarmacología
dc.subjectPharmacology
dc.titleIn vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamidees_ES
dc.typeArtículoes_ES
dspace.entity.typePublicationes
relation.isAuthorOfPublicationa594bc14-78fb-4463-bb01-204b60f3314e
relation.isAuthorOfPublicationfd42a96f-eb63-4a4e-b34c-68842904b28e
relation.isAuthorOfPublicationf623af41-20d4-43d8-9e2e-dd8d69954b62
relation.isAuthorOfPublication.latestForDiscoverya594bc14-78fb-4463-bb01-204b60f3314e

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
In_Dea_BMC_2009.JPG
Size:
115.02 KB
Format:
Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
No Thumbnail Available
Name:
In_Dea_BMC_2009.pdf
Size:
386.62 KB
Format:
Adobe Portable Document Format

Collections